Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Pharmacorp Rx Inc. ( (TSE:PCRX) ) is now available.
PharmaCorp Rx Inc. reported its Q2 2025 financial results, highlighting continued operational momentum and strategic acquisitions. The company completed the acquisition of a fourth pharmacy in Western Canada, reinforcing its national expansion ambitions. Despite a net loss due to investments in corporate infrastructure and deferred executive compensation, the company showed strong pharmacy-level contribution margins and same-store sales growth of 11.3% year-over-year. PharmaCorp’s recent credit agreement with CIBC will support its acquisition strategy, including a $5 million facility for its Pharmacist Co-Ownership Program, enhancing its operational platform and stakeholder engagement.
More about Pharmacorp Rx Inc.
PharmaCorp Rx Inc. is a growing national platform focused on pharmacist-led community pharmacy ownership. The company operates in the healthcare industry, primarily dealing with pharmacy services and has a strategic focus on expanding its network across Canada through acquisitions.
Average Trading Volume: 26,933
Technical Sentiment Signal: Hold
Current Market Cap: C$53.06M
For detailed information about PCRX stock, go to TipRanks’ Stock Analysis page.